References
1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance
for invasive fungal infections in hematopoietic stem cell transplant
recipients, 2001-2006: overview of the Transplant-Associated Infection
Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;
50: 1091-1100. 2010/03/12. DOI: 10.1086/651263.
2. des Champs-Bro B, Leroy-Cotteau A, Mazingue F, et al. Invasive fungal
infections: epidemiology and analysis of antifungal prescriptions in
onco-haematology. J Clin Pharm Ther 2011; 36: 152-160.
2011/03/04. DOI: 10.1111/j.1365-2710.2010.01166.x.
3. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment
outcome of invasive fungal infections in patients with hematological
malignancies. Int J Hematol 2012; 96: 748-757. 2012/11/01. DOI:
10.1007/s12185-012-1210-y.
4. Kobayashi R, Hori D, Sano H, et al. Risk Factors for Invasive Fungal
Infection in Children and Adolescents With Hematologic and Malignant
Diseases: A 10-year Analysis in a Single Institute in Japan.Pediatr Infect Dis J 2018; 37: 1282-1285. 2018/11/09. DOI:
10.1097/INF.0000000000002010.
5. Johnson LB and Kauffman CA. Voriconazole: a new triazole antifungal
agent. Clin Infect Dis 2003; 36: 630-637. 2003/02/21. DOI:
10.1086/367933.
6. Hohmann N, Kocheise F, Carls A, et al. Dose-Dependent Bioavailability
and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of
Voriconazole. Clin Pharmacokinet 2016; 55: 1535-1545. 2016/05/30.
DOI: 10.1007/s40262-016-0416-1.
7. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the
pharmacokinetics of voriconazole after single and multiple doses in
healthy volunteers. J Clin Pharmacol 2012; 52: 195-203.
2011/03/09. DOI: 10.1177/0091270010395510.
8. Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole
plasma concentrations in haematological patients: real life multicentre
experience. Mycoses 2012; 55: 483-492. 2012/03/21. DOI:
10.1111/j.1439-0507.2012.02186.x.
9. Hope WW. Population pharmacokinetics of voriconazole in adults.Antimicrob Agents Chemother 2012; 56: 526-531. 2011/11/09. DOI:
10.1128/AAC.00702-11.
10. Qi F, Zhu L, Li N, et al. Influence of different proton pump
inhibitors on the pharmacokinetics of voriconazole. Int J
Antimicrob Agents 2017; 49: 403-409. 2017/02/06. DOI:
10.1016/j.ijantimicag.2016.11.025.
11. Xu G, Zhu L, Ge T, et al. Pharmacokinetic/pharmacodynamic analysis
of voriconazole against Candida spp. and Aspergillus spp. in children,
adolescents and adults by Monte Carlo simulation. Int J Antimicrob
Agents 2016; 47: 439-445. 2016/05/18. DOI:
10.1016/j.ijantimicag.2016.02.016.
12. Tang D, Song BL, Yan M, et al. Identifying factors affecting the
pharmacokinetics of voriconazole in patients with liver dysfunction: A
population pharmacokinetic approach. Basic Clin Pharmacol Toxicol2019; 125: 34-43. 2019/02/05. DOI: 10.1111/bcpt.13208.
13. T, Eguchi S and Ieiri I. Impact of genetic polymorphisms in CYP2C9
and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug
Metab Pharmacokinet 2013; 28: 28-37. 2012/11/21. DOI:
10.2133/dmpk.dmpk-12-rv-085.
14. Kiang TK, Sherwin CM, Spigarelli MG, et al. Fundamentals of
population pharmacokinetic modelling: modelling and software. Clin
Pharmacokinet 2012; 51: 515-525. 2012/06/09. DOI:
10.2165/11634080-000000000-00000.
15. Liu P and Mould DR. Population pharmacokinetic-pharmacodynamic
analysis of voriconazole and anidulafungin in adult patients with
invasive aspergillosis. Antimicrob Agents Chemother 2014; 58:
4727-4736. 2014/06/11. DOI: 10.1128/AAC.02809-13.
16. Han K, Bies R, Johnson H, et al. Population pharmacokinetic
evaluation with external validation and Bayesian estimator of
voriconazole in liver transplant recipients. Clin Pharmacokinet2011; 50: 201-214. 2011/02/08. DOI: 10.2165/11538690-000000000-00000.
17. Han K, Capitano B, Bies R, et al. Bioavailability and population
pharmacokinetics of voriconazole in lung transplant recipients.Antimicrob Agents Chemother 2010; 54: 4424-4431. 2010/08/04. DOI:
10.1128/AAC.00504-10.
18. Chen C, Yang T, Li X, et al. Population Pharmacokinetics of
Voriconazole in Chinese Patients with Hematopoietic Stem Cell
Transplantation. Eur J Drug Metab Pharmacokinet 2019; 44:
659-668. 2019/05/02. DOI: 10.1007/s13318-019-00556-w.
19. Liu Y, Qiu T, Liu Y, et al. Model-based Voriconazole Dose
Optimization in Chinese Adult Patients With Hematologic Malignancies.Clin Ther 2019; 41: 1151-1163. 2019/05/14. DOI:
10.1016/j.clinthera.2019.04.027.
20. Chen K, Zhang X, Ke X, et al. Individualized Medication of
Voriconazole: A Practice Guideline of the Division of Therapeutic Drug
Monitoring, Chinese Pharmacological Society. Ther Drug Monit2018; 40: 663-674. 2018/09/08. DOI: 10.1097/FTD.0000000000000561.
21. Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics
Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole
Therapy. Clin Pharmacol Ther 2017; 102: 45-51. 2016/12/17. DOI:
10.1002/cpt.583.
22. Gastine S, Lehrnbecher T, Muller C, et al. Pharmacokinetic Modeling
of Voriconazole To Develop an Alternative Dosing Regimen in Children.Antimicrob Agents Chemother 2018; 62 2017/10/19. DOI:
10.1128/AAC.01194-17.
23. Friberg LE, Ravva P, Karlsson MO, et al. Integrated population
pharmacokinetic analysis of voriconazole in children, adolescents, and
adults. Antimicrob Agents Chemother 2012; 56: 3032-3042.
2012/03/21. DOI: 10.1128/AAC.05761-11.
24. Saini L, Seki JT, Kumar D, et al. Serum voriconazole level
variability in patients with hematological malignancies receiving
voriconazole therapy. Can J Infect Dis Med Microbiol 2014; 25:
271-276. 2014/11/06. DOI: 10.1155/2014/214813.
25. Kang S, Yee J, Kim JY, et al. Factors Associated With Voriconazole
Concentration in Pediatric Patients. Ther Drug Monit 2020; 42:
866-871. 2020/09/02. DOI: 10.1097/FTD.0000000000000804.
26. Veringa A, Geling S, Span LF, et al. Bioavailability of voriconazole
in hospitalised patients. Int J Antimicrob Agents 2017; 49:
243-246. 2016/12/26. DOI: 10.1016/j.ijantimicag.2016.10.010.
27. Kato K, Nagao M, Yamamoto M, et al. Oral administration and younger
age decrease plasma concentrations of voriconazole in pediatric
patients. J Infect Chemother 2016; 22: 27-31. 2015/11/06. DOI:
10.1016/j.jiac.2015.09.008.
28. Hirata A, Noto K, Ota R, et al. Voriconazole trough concentration
and hepatotoxicity in patients with low serum albumin. Int J Clin
Pharmacol Ther 2019; 57: 135-143. 2019/01/29. DOI: 10.5414/CP203345.
29. Blanco Dorado S, Maronas Amigo O, Latorre-Pellicer A, et al. A
multicentre prospective study evaluating the impact of proton-pump
inhibitors omeprazole and pantoprazole on voriconazole plasma
concentrations. Br J Clin Pharmacol 2020; 86: 1661-1666.
2020/02/29. DOI: 10.1111/bcp.14267.
30. Cojutti P, Candoni A, Forghieri F, et al. Variability of
Voriconazole Trough Levels in Haematological Patients: Influence of
Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP
Inhibitors plus CYP Inducers. Basic Clin Pharmacol Toxicol 2016;
118: 474-479. 2015/11/18. DOI: 10.1111/bcpt.12530.
31. Allegra S, De Francia S, De Nicolo A, et al. Effect of Gender and
Age on Voriconazole Trough Concentrations in Italian Adult Patients.Eur J Drug Metab Pharmacokinet 2020; 45: 405-412. 2020/01/23.
DOI: 10.1007/s13318-019-00603-6.
32. Allegra S, Fatiguso G, De Francia S, et al. Therapeutic drug
monitoring of voriconazole for treatment and prophylaxis of invasive
fungal infection in children. Br J Clin Pharmacol 2018; 84:
197-203. 2017/08/15. DOI: 10.1111/bcp.13401.
33. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug
monitoring in allogeneic hematopoietic stem cell transplant recipients.Bone Marrow Transplant 2005; 35: 509-513. 2005/01/18. DOI:
10.1038/sj.bmt.1704828.
34. Vreugdenhil B, van der Velden W, Feuth T, et al. Moderate
correlation between systemic IL-6 responses and CRP with trough
concentrations of voriconazole. Br J Clin Pharmacol 2018; 84:
1980-1988. 2018/05/11. DOI: 10.1111/bcp.13627.
35. Ter Avest M, Veringa A, van den Heuvel ER, et al. The effect of
inflammation on voriconazole trough concentrations in children. Br
J Clin Pharmacol 2017; 83: 678-680. 2016/11/20. DOI: 10.1111/bcp.13151.
36. Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma
concentrations in immunocompromised pediatric patients vary by CYP2C19
diplotypes. Pharmacogenomics 2014; 15: 1065-1078. 2014/08/02.
DOI: 10.2217/pgs.14.53.
37. Takahashi T, Mohamud MA, Smith AR, et al. CYP2C19 Phenotype and Body
Weight-Guided Voriconazole Initial Dose in Infants and Children after
Hematopoietic Cell Transplantation. Antimicrob Agents Chemother2021; 65: e0062321. 2021/06/08. DOI: 10.1128/AAC.00623-21.
38. Wang J, Xu H, Li R, et al. Model-Oriented Dose Optimization of
Voriconazole in Critically Ill Children. Antimicrob Agents
Chemother 2021; 65: e0049321. 2021/06/22. DOI: 10.1128/AAC.00493-21.
39. Farkas A, Daroczi G, Villasurda P, et al. Comparative Evaluation of
the Predictive Performances of Three Different Structural Population
Pharmacokinetic Models To Predict Future Voriconazole Concentrations.Antimicrob Agents Chemother 2016; 60: 6806-6812. 2016/09/08. DOI:
10.1128/AAC.00970-16.
40. Shi C, Xiao Y, Mao Y, et al. Voriconazole: A Review of Population
Pharmacokinetic Analyses. Clin Pharmacokinet 2019; 58: 687-703.
2019/01/29. DOI: 10.1007/s40262-019-00735-7.
41. Li ZW, Peng FH, Yan M, et al. Impact of CYP2C19 Genotype and Liver
Function on Voriconazole Pharmacokinetics in Renal Transplant
Recipients. Ther Drug Monit 2017; 39: 422-428. 2017/06/13. DOI:
10.1097/FTD.0000000000000425.
42. Tang D, Yan M, Song BL, et al. Population pharmacokinetics, safety
and dosing optimization of voriconazole in patients with liver
dysfunction: A prospective observational study. Br J Clin
Pharmacol 2021; 87: 1890-1902. 2020/10/04. DOI: 10.1111/bcp.14578.
43. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety
of voriconazole following intravenous- to oral-dose escalation regimens.Antimicrob Agents Chemother 2002; 46: 2546-2553. 2002/07/18. DOI:
10.1128/AAC.46.8.2546-2553.2002.
44. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and
safety of intravenous voriconazole in children after single- or
multiple-dose administration. Antimicrob Agents Chemother 2004;
48: 2166-2172. 2004/05/25. DOI: 10.1128/AAC.48.6.2166-2172.2004.
45. Wang T, Chen S, Sun J, et al. Identification of factors influencing
the pharmacokinetics of voriconazole and the optimization of dosage
regimens based on Monte Carlo simulation in patients with invasive
fungal infections. J Antimicrob Chemother 2014; 69: 463-470.
2013/10/03. DOI: 10.1093/jac/dkt369.
46. Theuretzbacher U, Ihle F and Derendorf H.
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin
Pharmacokinet 2006; 45: 649-663. 2006/06/29. DOI:
10.2165/00003088-200645070-00002.
47. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety,
and tolerability of voriconazole in immunocompromised children.Antimicrob Agents Chemother 2010; 54: 4116-4123. 2010/07/28. DOI:
10.1128/AAC.00896-10.
48. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics,
metabolism and bioavailability of the triazole antifungal agent
voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol2009; 68: 906-915. 2009/12/17. DOI: 10.1111/j.1365-2125.2009.03534.x.
49. Muto C, Shoji S, Tomono Y, et al. Population pharmacokinetic
analysis of voriconazole from a pharmacokinetic study with
immunocompromised Japanese pediatric subjects. Antimicrob Agents
Chemother 2015; 59: 3216-3223. 2015/03/25. DOI: 10.1128/AAC.04993-14.
50. Karlsson MO, Lutsar I and Milligan PA. Population pharmacokinetic
analysis of voriconazole plasma concentration data from pediatric
studies. Antimicrob Agents Chemother 2009; 53: 935-944.
2008/12/17. DOI: 10.1128/AAC.00751-08.
51. Wei X, Zhao M, Fu P, et al. Risk factors associated with
insufficient and potentially toxic voriconazole plasma concentrations:
an observational study. J Chemother 2019; 31: 401-407.
2019/07/31. DOI: 10.1080/1120009X.2019.1646974.
52. Dote S, Sawai M, Nozaki A, et al. A retrospective analysis of
patient-specific factors on voriconazole clearance. J Pharm Health
Care Sci 2016; 2: 10. 2016/04/21. DOI: 10.1186/s40780-016-0044-9.
53. Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of
voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in
renal transplant recipients. Br J Clin Pharmacol 2018; 84:
1587-1597. 2018/04/03. DOI: 10.1111/bcp.13595.
54. Chantharit P, Tantasawat M, Kasai H, et al. Population
Pharmacokinetics of Voriconazole in Patients With Invasive
Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and
Dosage Optimization. Ther Drug Monit 2020; 42: 872-879.
2020/09/19. DOI: 10.1097/FTD.0000000000000799.
Table1.Demographic and clinical information